Pooled phase III analyses show benefits of Ryzodeg (insulin degludec/insulin aspart) in type 2 diabetes- Novo Nordisk

New analyses demonstrate that Ryzodeg (insulin degludec/insulin aspart), from Novo Nordisk, achieved successful glycaemic control with significantly lower rates of hypoglycaemia and nocturnal hypoglycaemia in patients with type 2 diabetes versus BIAsp 30 and/or a basal-bolus regimen of insulin degludec and insulin aspart. The analyses of pooled data from five 26-week treat-to-target phase IIIa/b clinical studies highlighted that these benefits were delivered to patients irrespective of baseline HbA1c, disease duration or body mass index.

The results also revealed that Ryzodeg versus both comparators resulted in statistically significant reductions in fasting plasma glucose, and a lower insulin dose with significant differences in patients with BMI less than 30 or a disease duration longer than 10 years. These findings were presented at the 23rd World Diabetes Congress of the International Diabetes Federation.

Comment: As a combination of two distinct insulin analogues, Ryzodeg is the first combination of a basal insulin with a long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.